INS and COVID-19: Very interestingly, the data showed that preadmission usage of GLP-1RAs was associated with a reduction in mortality rate in patients with DM and COVID-19, independently of gender, age, gender, cardiovascular disease, hypertension, and the use of metformin and/or insulin (110).